

Fernando Velayos, M.D.

Assistant Professor of Medicine
Division of Gastroenterology
Associate Director of Translational Research
UCSF Center for Crohn's and Colitis

Academic Office and Clinic:

Division of Gastroenterology
2330 Post Street, Suite 610
San Francisco, CA 94115
Phone: 415-502-4444
Fax: 415-502-2249
Email: fernando.velayos@ucsf.edu



Active Projects

- Chemoprevention for IBD-related colorectal cancer
- Molecular markers of dysplasia and progression in IBD
- Adherence to surveillance colonoscopy in IBD
- Natural history of dysplasia in IBD
- Surgical volume and outcomes in IBD
- Predictors of outcomes in IBD

Techniques in Use

- Prospective/retrospective observational studies
- Administrative databases
- Quality of life measures
- Meta-analysis
- Decision-analysis
- Outcomes research

Education

- 1988-1992 University of California, Los Angeles, B.S. Summa Cum Laude, Biology
- 1992-1997 University of California, San Francisco M.D. MD with Thesis, Alpha Omega Alpha

Training

- 1997-1998 University of California, San Francisco Intern Medicine
- 1998-2000 University of California, San Francisco Resident Medicine
- 2000-2001 University of California, San Francisco Chief resident Medicine
- 2001-2004 University of California, San Francisco Fellow Gastroenterology
- 1/04-6/04 Mayo Clinic, Rochester MN, Fellow Inflammatory Bowel Disease
- 2004-2005 University of California, Berkeley MPH Epidemiology

Certification

- 1997 Diplomate, National Board of Medical Examiners
- 1998 Medical License, Medical Board of California
- 1998 Drug Enforcement Administration Certificate
- 2001 Diplomate in Internal Medicine, American Board of Internal Medicine
- 2004 Medical License, Medical Board of Minnesota
- 2005 Diplomate in Gastroenterology, American Board of Internal Medicine

Memberships and Affiliations

- 2002-now American Gastroenterological Association

- 2002-now American College of Gastroenterology
- 2002-now American Society of Gastrointestinal Endoscopy
- 2002-now Crohn's and Colitis Foundation of America
- 2004-now Northern California Society of Clinical Gastroenterology

Service to Professional Organizations

- 2005-now National Patient Education Committee, Crohn's and Colitis Foundation of America
- 2006-now Clinical Trials Review Committee, Crohn's and Colitis Foundation of America
- 2007-now American Gastroenterological Association (AGA), Faculty, Inflammatory Bowel Disease Investing in the Future Mentorship Program
- 2008-now Medical Advisory Committee, Northern California Crohn's and Colitis Foundation (CMAC)
- 2009 Northern California Society of Clinical Gastroenterology, President Elect
- 2009-now Councilor and Nominating Committee, Intestinal Disorders Section, AGA

Editorial Boards

- 2006-Present Inflammatory Bowel Diseases Journal
- 2007-Present Gastroenterology & Hepatology
- 2009-Present Clinical Gastroenterology and Hepatology

Selected Publications

- **Velayos FS**, Allen BA, Conrad PG, Gum J, Karkar S, Chung DC, Truta B, Sleisenger MH, Kim YS, Terdiman JP. Low rate of microsatellite instability in young patients with adenomas: Reassessing the Bethesda Guidelines. *American Journal of Gastroenterology*. 2005 May; 100(5):1143-9.
- **Velayos FS**, Terdiman JP, Walsh JM. Effect of 5-Aminosalicylate use on colorectal cancer and dysplasia risk: A systematic review and meta-analysis of observational studies. *American Journal of Gastroenterology*. 2005 June; 100: 1345-1353.
- Jess T, Loftus EV, **Velayos FS**, Harmsen WS, Zinsmeister AR, Smyrk TC, Schleck CD, Tremaine WJ, Melton LJ 3rd, Munkholm P, Sandborn WJ. Risk of intestinal cancer in inflammatory bowel disease: a population-based study from Olmsted County, Minnesota. *Gastroenterology*. 2006 Apr;130(4):1039-46.
- **Velayos FS**, Loftus EV, Jess T, Harmsen WS, Bida J, Zinsmeister AR, Tremaine WJ, Sandborn WJ. Predictive and protective factors associated with colorectal cancer in ulcerative colitis: A case-control study. *Gastroenterology*. 2006 Jun;130(7):1941-9.
- Jess T, Loftus EV, **Velayos FS**, Harmsen WS, Zinsmeister AR, Smyrk TC, Tremaine WJ, Melton LJ 3rd, Munkholm P, Sandborn WJ. Incidence and prognosis of colorectal dysplasia in inflammatory bowel disease: a population-based study from Olmsted County, Minnesota. *Inflammatory Bowel Disease*. 2006 Aug;12(8):669-76
- Jess T, Loftus E, **Velayos FS**, Harmsen WS, Winther KV, Zinsmesiter AR, Tremaine WJ, Munkholm P, Sandborn WJ. Risk Factors for Cancer and Dysplasia in Inflammatory Bowel Disease: A Nested Case-Control Study of Population-Based Cohorts from Copenhagen County and Olmsted County. *American Journal of Gastroenterology*, 2007 Apr; 102(4) 829-36.
- **Velayos F** and Mahadevan U. Management of Steroid-Dependent Ulcerative Colitis: Immunomodulatory Agents, Biologics, or Surgery? *Clinical Gastroenterology and Hepatology*, 2007 Jun 5 (6): 668-671.
- Truta B, Chen YY, Blanco AM, Deng G, Conrad PG, Kim YH, Park ET, Kakar S, Kim YS, **Velayos F**, Sleisenger MH, Terdiman JP. Tumor histology helps to identify Lynch syndrome among colorectal cancer patients. *Familial Cancer*. 2008 Feb; 7(3):267-74.
- Rubin DT, Cruz-Correa MR, Gasche C, Jass JR, Lichtenstein GR, Montgomery EA, Riddell RH, Rutter MD, Ullman TA, **Velayos FS**, Itzkowitz S; 5-ASA in Colorectal Cancer Prevention

Meeting Group. Colorectal cancer prevention in inflammatory bowel disease and the role of 5-aminosalicylic acid: a clinical review and update. *Inflammatory Bowel Disease*. 2008 Feb;14(2):265-74.

- Altschuler A, Collins B, Lewis JD, **Velayos F**, Allison JE, Hutfless S, Liu L, Herrinton LJ. Gastroenterologists' attitudes and self-reported practices regarding inflammatory bowel disease. *Inflammatory Bowel Disease*. 2008 Jul; 14(7):992-999
- Pressman AR, Hutfless S, **Velayos FS**, Fireman B, Lewis JD, Allison JE, Abramson O, Herrinton LJ. Patterns of Infliximab use among Crohn's disease patients in a community setting. *Inflammatory Bowel Disease* 2008 Sep; 14(9): 1265-1272
- **Velayos FS**. Colon cancer surveillance in inflammatory bowel disease patients: current and emerging practices. *Expert Review in Gastroenterology and Hepatology*. 2008 Dec; 2(6): 817-825
- Ravishankar PG, **Velayos FS**. Forecasting cyclosporine success or failure. *Inflamm Bowel Dis*. 2009 Jan;15(1):152-3.
- Herrinton LJ, Liu L, Fireman B, Lewis JD, Allison JE, Flowers N, Hutfless S, **Velayos FS**, Abramson O, Altschuler A, Perry GS. Time Trends in Therapies and Outcomes for Adult Inflammatory Bowel Disease, Northern California, 1998-2005. *Gastroenterology* 2009 2009 Aug;137(2):502-11.
- Rubenstein JH, Waljee A, Jeter J, **Velayos FS**, Ladabaum U, Higgins PD. Cost-effectiveness of Ulcerative Colitis Surveillance in the Setting of 5-aminosalicylates. *American Journal of Gastroenterology*. 2009 Sep;104(9):2222-32.
- Lewis JD, Abramson O, Pascua M, Liu L, Asakura LM, **Velayos FS**, Hutfless SM, Allison JE, Herrinton LJ. Timing of Myelosuppression during Thiopurine Therapy for Inflammatory Bowel Disease: Implications for Monitoring Recommendations. *Clin Gastroenterol Hepatol*. 2009 Nov;7(11):1195-201; quiz 1141-2..
- Melmed GY, Spiegel BM, Bressler B, Cheifitz AS, Devlin SM, Harrell LE, Irving PM, Jones J, Kozuch PL, **Velayos PS**, Baudoo L, Sparrow MP, Siegel CA. The appropriateness of concomitant immunomodulators with anti-tumor necrosis factor agents for Crohn's disease: one size does not fit all. *Clin Gastroenterol Hepatol*. 2010 Aug;8(8):655-9.
- **Velayos FS**, Liu L, Lewis JD, Allison JE, Flowers N, Hutfless S, Abramson O, Perry GS, Herrinton LJ. Prevalence of colorectal cancer surveillance for ulcerative colitis in an integrated health care delivery system. *Gastroenterology*. 2010 Nov;139(5):1511-8.
- Abramson O, Durant M, Mow W, Finley A, Kodali P, Wong A, Tavares V, McCroskey E, Liu L, Lewis JD, Allison JE, Flowers N, Hutfless S, **Velayos FS**, Perry GS, Cannon R, Herrinton LJ. Incidence, prevalence, and time trends of pediatric inflammatory bowel disease in Northern California, 1996 to 2006. *J Pediatr*. 2010 Aug;157(2):233-239.e1.

Book Chapters

- **Velayos FS**. Gastrointestinal Bleeding. In Weiner-Kronish (ed): *Critical Care Secrets*. 3 ed. Hanley & Belfus, Inc. Philadelphia 2002.
- **Velayos FS**, Varma M, Terdiman JP. Polyposis and Familial Cancer Syndromes. In Michael Kochman and Doug Faigel (eds): *Endoscopic Oncology: Gastrointestinal Endoscopy and Cancer Management*. Humana Press, Inc. 2006
- Yang J, **Velayos FS**. Gastrointestinal Bleeding. In Weiner-Kronish (ed): *Critical Care Secrets*. 4 ed. Hanley & Belfus, Inc. Philadelphia 2007
- **Velayos FS** Cancer and Dysplasia in Inflammatory Bowel Disease. In Loftus (ed): *Blackwell Clinical Handbook: Inflammatory Bowel Disease*. 1ed. Blackwell Publishing. *In press*.

Invited Reviews and Editorials

- **Velayos FS**, Mahadevan U. Diagnostic Techniques in Inflammatory Bowel Disease. *CCFA Foundation Focus*. Summer 2002: 3-9.

- **Velayos FS** Expert Column: Cancer Prevention of Ulcerative Colitis. Medscape.com. Published on-line December 2006.
- **Velayos FS** Compliance, Mucosal Healing, and the Chemoprevention of Colorectal Cancer. A Clinical Monograph. *Gastroenterology and Hepatology*. December 2006.
- **Velayos FS** Examining Current and Emerging Treatment Options in Ulcerative Colitis: Strategies to Improve Patient Outcomes. *Published on line: PeerView.com CME-Mar 2007*
- **Velayos FS** Research update on Colorectal Cancer in Inflammatory Bowel Disease from Digestive Diseases Week 2007. *Published on line: Medscape.com*. May 2007
- **Velayos FS** Research updates from Digestive Diseases Week 2007. *Gastroenterology and Hepatology*. August 2007.
- **Velayos FS** Digestive Diseases Week 2007 Meeting Report. *IBD Monitor*. September 2007.
- **Velayos FS** Examining the Ulcerative Colitis-Colorectal Cancer Link. *Expert Insights*. October 2007.
- **Velayos FS** Research update on Diagnostic Advances in Inflammatory Bowel Disease from the 2007 American College of Gastroenterology Congress. *Published on line: Medscape.com*. October 2007.
- **Velayos FS**. Advances in Ulcerative Colitis-volume 3: Ulcerative Colitis and Cancer Chemoprevention. *Published on line: Medscape.com* November 2007.
- **Velayos FS** and Sandborn WJ. Positioning Biologic Therapy for Crohn's Disease and Ulcerative Colitis. *Current Gastroenterology Reports*. 2007. Dec; 9(6): 521-527.
- Bahamonde L and **Velayos FS**. The fungus among us: Pneumocystis in Inflammatory Bowel Disease. *Inflammatory Bowel Disease*. 2008 Jan;14(5):721-722.
- Lichtenstein GR, Rubin DT, Sabesin SM, **Velayos FS**, Vitat P. Maximizing patient adherence and clinical outcomes with mesalamine in mildly-to-moderately active ulcerative colitis. *Reviews in Gastroenterological Disorders*. 2008 Winter; 8(1): 21-30.
- Sparrow MP, Irving PM, Baidoo L, Bressler B, Cheifetz AS, Devlin S, Harrell LE, Jones J, Kozuch PL, Melmed GY, **Velayos FS**, Siegel CA. Current Controversies in Crohn's Disease; A Roundtable Discussion of the BRIDGE Group. *Gastroenterology & Hepatology*, 2008 Oct 4(10): 713-720.
- Sraju P and **Velayos FS**. Predicting cyclosporine success or failure. *Inflammatory Bowel Disease*. 2009 Jan; 15(1): 152-3
- Mahadevan U and **Velayos FS**. Digestive Diseases Week 2009 Meeting Report. *IBD Monitor*. July 2009.
- **Velayos FS** and Sandborn WJ. Use of Azathioprine and 6MP in Post-Operative Crohn's. Changing Natural History of Just Along for the Ride? *American Journal of Gastroenterology* 2009 Aug;104(8):2097-9.
- **Velayos FS**. Deciding to operate for low-grade colorectal dysplasia in UC: How much does the colon cost? How much is it worth. *Gastrointestinal Endoscopy* [epub ahead of print]
- Siao D and **Velayos FS**. The Good the Bad and The Ugly: Adverse Events with Crohn's Therapies. *Inflammatory Bowel Diseases*, 2010 Aug;16(8):1443-4.
- Siao D and **Velayos FS**. Surgery for low-grade colorectal dysplasia in UC: Decisions, decisions. *Inflammatory Bowel Diseases*, 2010 Aug;16(8):1443-4.